WASHINGTON— Delivering a monumental blow to Big Pharma's decades-long exploitation of American taxpayers, President Donald Trump announced on Friday, September 18, 2026, that all 50 states—alongside the District of Columbia and Puerto Rico—have joined the administration's revolutionary "Most-Favored-Nation" (MFN) Medicaid prescription drug pricing model.
Surrounded in the Oval Office by Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz, and state governors, President Trump declared the total national adoption of the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) model. The nationwide framework ensures that state Medicaid programs obtain supplemental rebates directly from pharmaceutical manufacturers, forcing domestic prices to match the lowest costs charged in other high-income, developed nations.
The historic expansion ends the globalist status quo where American families subsidize foreign healthcare systems. According to projections from the White House Council of Economic Advisers, the nationwide MFN initiative will generate an astonishing $64.3 billion in net taxpayer savings over the next decade—yielding $36.6 billion for federal coffers and returning $27.6 billion directly to state budgets to fund critical local healthcare needs.
To date, the Trump administration has brokered voluntary MFN agreements with 26 major pharmaceutical manufacturers—representing 89% of the domestic branded drug market—covering treatments for oncology, diabetes, asthma, and severe chronic illnesses. Coupled with direct-to-consumer savings on the *TrumpRx.gov* platform, the total projected savings from President Trump's MFN strategy are set to exceed $600 billion over ten years.
"This one thing alone should win us the midterms," President Trump stated, highlighting the administration's relentless push to slash cost-of-living burdens for working families. While legacy media outlets and pharmaceutical lobbyists scramble to downplay the achievement, the 50-state Medicaid alignment demonstrates how conservative executive leadership, market leverage, and direct negotiation are dismantling predatory price-gouging and putting American patients first.
